IL2 and neoplasm: The tumor-nonspecific OVA SLP and the tumor-specific altered-self SLP Gp10017 were both adjuvanted with imiquimod and supplemented with IL-2, and the lymphocytic choriomeningitis virus (LCMV)-derived tumor-nonspecific Gp34 SLP18 was supplemented with TLR9 agonist CpG as adjuvant (Fig. 7a–d).